Gene News and Research

Latest Gene News and Research

Mirimus develops enhanced tools for reversible gene suppression

Over the last decades, RNA interference (RNAi) has become an indispensable tool for functional genetic studies by harnessing the power of a cell intrinsic mechanism enabling reversible gene silencing.

17 Dec 2013

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin gene in development for the treatment of TTR-mediated amyloidosis.

17 Dec 2013

Utah researchers discover naturally occurring genetic variation that cause inflammatory arthritis

University of Utah researchers have discovered a naturally occurring genetic variation in mice that predisposes carriers toward developing severe, inflammatory arthritis. The finding implicates a new class of genes in arthritis progression, potentially opening doors to new treatment options.

17 Dec 2013

Two existing drugs show promise as potential treatments for cervical cancer

Two existing drugs - one the active ingredient in an anti-fungal medication and the other now used to control iron levels in the blood - both show promise as potential treatments for cervical cancer, according to newly published research by scientists at Rutgers New Jersey Medical School.

17 Dec 2013

Scientists establish a goal of creating vaccine gene chip to speed up vaccine testing

Testing the efficacy of vaccines in clinical trials takes years, even decades. Yet challenging infections like HIV, malaria and dengue are striking today. To speed up vaccine testing, scientists at the Emory Vaccine Center have established a goal of creating a "vaccine gene chip."

17 Dec 2013

Research findings point to possible new strategy for treating ALS

Amyotrophic lateral sclerosis, better known as Lou Gehrig's disease, is a devastating illness that gradually robs sufferers of muscle strength and eventually causes a lethal, full-body paralysis. The only drug available to treat the disease extends life spans by a meager three months on average.

17 Dec 2013

New regulation for cancer-causing protein may help develop targeted therapies

Researchers with the Cincinnati Cancer Center (CCC) and the University of Cincinnati (UC) Cancer Institute have discovered a new regulation for the cancer-causing protein KRas which may help with the development of targeted therapies for patients with a KRas mutation.

17 Dec 2013

PAM50 FDA-cleared breast cancer test to be launched at ARUP Laboratories

The PAM50 breast cancer signature developed at the University of Utah and Huntsman Cancer Institute received FDA approval and will launch at ARUP Laboratories in Salt Lake City. The test utilizes gene expression data from 50 genes weighted together with clinical variables to generate a risk category and numerical score to assess a patient's risk of distant recurrence at ten years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), Hormone Receptor-Positive (HR+) breast cancer.

16 Dec 2013

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML).

16 Dec 2013

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results from the I-SPY 2 trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

Study could lead towards a personalised medicine for chemoresistant lymphomata

To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumours would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata.

16 Dec 2013

New discovery could help combat spread of sleeping sickness

A new discovery by scientists could help combat the spread of sleeping sickness.

15 Dec 2013

Four U.S. researchers to receive grants to improve cognition in individuals living with Down syndrome

The Scientific Advisory Board of the Jerome Lejeune Foundation USA has recommended 4 U.S. researchers to receive grants from the Foundation for its second funding cycle of 2013.

15 Dec 2013

Eleven researchers receives 2014 DeLill Nasser Award for Professional Development in Genetics

The Genetics Society of America (GSA) is pleased to announce the selection of eleven early career researchers - five graduate students and six postdoctoral researchers - as recipients of a spring 2014 DeLill Nasser Award for Professional Development in Genetics.

15 Dec 2013

CHOP scientist receives 2013 E. Donnall Thomas Prize for scientific, clinical research in hemophilia

Katherine A. High, M.D., of The Children's Hospital of Philadelphia (CHOP) was honored for her trailblazing scientific and clinical research in the bleeding disorder hemophilia when she received the 2013 E. Donnall Thomas Prize from the American Society of Hematology (ASH) at its annual meeting on Dec. 9 in New Orleans.

15 Dec 2013

Research reveals that deletion of Epac1 gene protects from fatal rickettsiosis

Researchers at the University of Texas Medical Branch at Galveston have discovered a way to block a disease pathway that could be a breakthrough in defeating some of the world's most devastating human infections.

14 Dec 2013

Scientists reveal how two genes interact to kill broad range of cancer cells

Scientists from Virginia Commonwealth University Massey Cancer Center have revealed how two genes interact to kill a wide range of cancer cells. Originally discovered by the study's lead investigator Paul B. Fisher, M.Ph., Ph.D., the genes known as mda-7/IL-24 and SARI could potentially be harnessed to treat both primary and metastatic forms of brain, breast, colon, lung, ovary, prostate, skin and other cancers.

14 Dec 2013

CHOP scientist receives 2013 E. Donnall Thomas Prize for research in bleeding disorder hemophilia

Katherine A. High, M.D., of The Children's Hospital of Philadelphia was honored for her trailblazing scientific and clinical research in the bleeding disorder hemophilia when she received the 2013 E. Donnall Thomas Prize from the American Society of Hematology at its annual meeting on Dec. 9 in New Orleans.

14 Dec 2013

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosignaz Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment.

13 Dec 2013

Spaceflights cause cellular-level damage and may lead to long-term vision problems

Those who travel to space are rewarded with a beautiful sight - planet Earth. But the effects of space travel on the human sense of sight aren't so beautiful. More than 30 percent of astronauts who returned from two-week space shuttle missions and 60 percent who spent six months aboard the International Space Station were diagnosed with eye problems. Two recent investigations examined mechanisms that may explain eye changes in spaceflight, help find ways to minimize this health risk to astronauts and eventually prevent and treat eye diseases on Earth.

13 Dec 2013

Gene News and Research

Latest Gene News and Research

Mirimus develops enhanced tools for reversible gene suppression

Alnylam initiates Phase II study with ALN-TTRsc for treatment of ATTR

Utah researchers discover naturally occurring genetic variation that cause inflammatory arthritis

Two existing drugs show promise as potential treatments for cervical cancer

Scientists establish a goal of creating vaccine gene chip to speed up vaccine testing

Research findings point to possible new strategy for treating ALS

New regulation for cancer-causing protein may help develop targeted therapies

PAM50 FDA-cleared breast cancer test to be launched at ARUP Laboratories

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Study could lead towards a personalised medicine for chemoresistant lymphomata

New discovery could help combat spread of sleeping sickness

Four U.S. researchers to receive grants to improve cognition in individuals living with Down syndrome

Eleven researchers receives 2014 DeLill Nasser Award for Professional Development in Genetics

CHOP scientist receives 2013 E. Donnall Thomas Prize for scientific, clinical research in hemophilia

Research reveals that deletion of Epac1 gene protects from fatal rickettsiosis

Scientists reveal how two genes interact to kill broad range of cancer cells

CHOP scientist receives 2013 E. Donnall Thomas Prize for research in bleeding disorder hemophilia

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

Spaceflights cause cellular-level damage and may lead to long-term vision problems

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Neurology/Neuroscience - 2nd edition

Industry focus eBook: Genomics (4th edition)

Industry Focus eBook - Clinical & Point of Care Diagnostics (1st edition)

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition)

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective